Preparing for FDA Inspection: Compliance Gaps That Lead to 483 Observations

Connect With An Expert

FDA warning letters jumped 50% in 2025. Ensure FDA inspection readiness by addressing the compliance execution gaps that lead to 483 observations and risks.

An Increase in FDA Inspections Demands a Greater Emphasis on Compliance

A changing Food and Drug Administration (FDA) landscape has brought increased scrutiny, and more companies are scrambling to ensure compliance. Warning letters issued by the Center for Drug Evaluation and Research (CDER) rose by 50% in 2025. And with the FDA planning to aggressively expand hiring, that number is unlikely to decrease in 2026.

One reason for that increase stems from the launch of the FDA’s internal AI system, which analyzes companies’ internal data such as past inspection outcomes and anomalies in compliance data to flag high-risk facilities. While this technology may lower the number of random inspections assigned, it puts your company’s every step under a microscope.

Top Reasons for Form 483 Observations

Inspections are revealing compliance gaps at every stage of the product life cycle, from R&D to manufacturing to quality assurance. Some of the most common compliance gaps identified during inspections include:

Incorrect labeling
Poor aseptic control
Equipment maintenance issues
Missing or out-of-date standard operating procedures (SOPs)
Absent corrective and preventative action (CAPA) systems
Lack of deviation management
Insufficient environmental monitoring
Poor sample management

The Cost of Form 483 Observations

These compliance gaps contribute directly to Form 483 observations. Observations can cause productivity delays, but the real risk lies in failing to address gaps. Companies are typically required to confirm receipt of a Form 483 and respond within 15-30 days. The cost of receiving a warning letter or, more severely, a consent decree can greatly outweigh the cost of proactive action.

For medical device companies, one study found that observations, recalls, warning letters, consent decrees and associated legal fees cost the industry almost $9 billion annually. Should a Form 483 observation lead to a recall, some research puts that cost at nearly $10 million. Neither of these figures account for lost sales or long-term reputational damage.

To avoid such risks, your company must invest in a proactive, rather than a reactive, approach to the threat of audits.

Looking to Ensure FDA Inspection Readiness?

Partner with Actalent to address compliance risks.

Fostering a Proactive Compliance Culture

The key to a thriving company free of compliance risks is sustaining continuous inspection readiness. This requires fostering a culture committed to taking a proactive approach to compliance best practices. To build this environment, your company will need to put renewed focus on:

Conducting routine internal audits to identify compliance gaps before the FDA does
Maintaining updated SOPs for processes like sample preparation and instrument operation
Prioritizing data integrity for both your company and third-party vendors through accessible, organized and updated documentation, including method validation, maintenance records and logbooks
Requiring regular trainings on regulatory expectations for both new and senior staff to stay ahead of shifting compliance demands

Scaling Compliance Initiatives with Strategic Partners

To avoid running afoul of FDA inspections, consider working with a strategic partner who can provide managed support to help reduce variability, close compliance gaps and ensure consistent execution at scale. These partners can help you address immediate gaps and pain points while building long-term strategies for ensuring ongoing compliance.

Before an FDA Inspection

Internal audits should be conducted at regular intervals to identify potential compliance issues. While these should be a priority for every company, routine audits are crucial if your company is at higher risk for an FDA inspection because of previous observations.

Bringing in a third-party strategic partner to conduct an internal audit can provide an outside perspective from experts with extensive knowledge of FDA regulations. These partners will complete a gap assessment that identifies where you may be at risk of a Form 483 observation. From there, they can help mitigate these risks by providing guidance on corrective and preventative action.

After Receiving a Form 483 Observation

If you’ve received a Form 483 observation, these partners can provide critical support during the response period by helping you interpret the observation and define an appropriate CAPA strategy for submission to the FDA. While full remediation efforts typically cannot be launched within the initial response window, they can help you assess the underlying issues, identify root causes and outline corrective and preventive actions that demonstrate a clear commitment to compliance. Following submission, these partners can then support execution of the remediation plan and preparation for follow up inspections, helping ensure sustained compliance.

Success Story: Conducting a Gap Analysis and Audit for a Medical Device Innovator

Our client is one of the world’s leading manufacturers of medical devices for minimally invasive procedures. After several changes in leadership, our client discovered that key aspects of their R&D weren’t in compliance — specifically, SOPs. This put them at risk for an FDA 483 warning letter.

Our experts completed a thorough audit of the client’s QMS components and provided a gap analysis to map out a path to compliance. Our auditors identified and addressed misaligned SOPs relative to document and record control, training and competency, and corrective and preventative action. Ultimately, we helped ensure our client stays in compliance with a multitude of regulatory bodies, avoiding significant financial and reputational harm.

Best-in-class Support for Maintained Inspection Readiness

Actalent’s Scientific Support Services is a strategic solution for connecting execution, workforce capabilities and regulatory compliance. Our team of best-in-class experts brings deep expertise in laboratory management, process design, compliance, quality, efficiency and facilities infrastructure.

We can help strengthen quality operations by improving efficiencies and providing guidance on NCRs, CAPAs and warning‑letter remediation. Our processes adhere to regulatory guidelines to ensure quality and compliance, including:

ISO-certified delivery locations
Good Laboratory Practice (GLP)
Good Manufacturing Practices (GMP)
Food and Drug Administration
National Sanitation Foundation (NSF)

We also offer a robust quality management system to help you define, improve and control processes while facilitating a better trained, more engaged workforce for more consistent results.

Frequently Asked Questions
About Preparing for FDA Inspection

What are common causes of FDA Form 483 observations?

Common causes for FDA Form 483 observations include poor documentation, anomalies in compliance data and failure to follow procedures, among others.

Why do compliance issues exist even when quality management systems are in place?

Even with quality management systems in place, consistent compliance can be difficult to achieve. Actalent’s Scientific Support Services connects execution, workforce capabilities and regulatory compliance to strengthen operations and address compliance risks.

How can companies maintain continuous inspection readiness?

To maintain inspection readiness, companies should take a proactive approach that includes internal audits, regular regulatory trainings for staff, maintaining updated standard operating procedures (SOPs) and prioritizing data integrity both internally and for third-party vendors.

Preparing for FDA Inspection: Compliance Gaps That Lead to 483 Observations